VIR Jason O'Byrne sells $38K worth of shares
Nov 19, 2025, 5:37 AM
0.00%
What does VIR do
Vir Biotechnology is a San Francisco-based clinical-stage immunology company focusing on treatments for infectious diseases, with a pipeline targeting HDV, HBV, HIV, and other viruses. The company went public on October 11, 2019, and employs 587 full-time staff.
Jason O'Byrne sold 6,799 shares of VIR on 17 November at $5.56 per share, worth a total of $38K. They now own 110,701 VIR shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.